Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation

Serenella Rotondo, Katarzyna Krauze-Brzósko, Stefano Manarini, Virgilio Evangelista, Chiara Cerletti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

5-Lipoxygenase/cyclooxygenase inhibitors, possessing anti-inflammatory action and gastric safety due to cyclooxygenase-2 and 5-lipoxygenase inhibition and antiplatelet activity due to cyclooxygenase-1 blockade, would be beneficial in the treatment of ischemic disease because they may reduce, at the same time, inflammation, underlying the atherosclerotic process, and platelet activation, responsible for acute thrombotic events. In this study, we characterized the antiplatelet effects of the new 5-lipoxygenase/cyclooxygenase inhibitor licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3,dihydro-1H- pyrrolizine-5-yl]-acetic acid. Licofelone completely prevented platelet aggregation induced in platelet-rich plasma by threshold aggregating concentrations of arachidonic acid (0.87±0.14 mM) at threshold inhibitory concentrations of 0.75±0.35 μM (n=5). Platelet-rich plasma aggregation induced by threshold aggregating concentrations of collagen/adrenalin (0.3±0.05 μg/ml and 0.4±0.1 μM, respectively) was reduced to 3.2±2% of control at licofelone 100 μM, (P2 (TxB2) production by all the agonists tested at concentrations between 0.5 and 50 μM. At this concentration, TxB2 production was reduced at values similar to those of unstimulated platelets. These results indicate that, at clinically relevant concentrations, licofelone exerts a potent antiplatelet effect mediated by the inhibition of cyclooxygenase-1 activity.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalEuropean Journal of Pharmacology
Volume488
Issue number1-3
DOIs
Publication statusPublished - Mar 19 2004

Fingerprint

licofelone
Lipoxygenase Inhibitors
Cyclooxygenase 1
Platelet Activation
Platelet-Rich Plasma
Cyclooxygenase Inhibitors
Arachidonate 5-Lipoxygenase
Cyclooxygenase 2
Platelet Aggregation
Arachidonic Acid
Epinephrine
Stomach
Anti-Inflammatory Agents
Collagen
Blood Platelets
Inflammation
Safety

Keywords

  • Cyclooxygenase-lipoxygenase inhibitor
  • Licofelone
  • Platelet aggregation, human
  • Thromboxane A2

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. / Rotondo, Serenella; Krauze-Brzósko, Katarzyna; Manarini, Stefano; Evangelista, Virgilio; Cerletti, Chiara.

In: European Journal of Pharmacology, Vol. 488, No. 1-3, 19.03.2004, p. 79-83.

Research output: Contribution to journalArticle

Rotondo, Serenella ; Krauze-Brzósko, Katarzyna ; Manarini, Stefano ; Evangelista, Virgilio ; Cerletti, Chiara. / Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. In: European Journal of Pharmacology. 2004 ; Vol. 488, No. 1-3. pp. 79-83.
@article{14dd3b274597408e9615886f35c96ef6,
title = "Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation",
abstract = "5-Lipoxygenase/cyclooxygenase inhibitors, possessing anti-inflammatory action and gastric safety due to cyclooxygenase-2 and 5-lipoxygenase inhibition and antiplatelet activity due to cyclooxygenase-1 blockade, would be beneficial in the treatment of ischemic disease because they may reduce, at the same time, inflammation, underlying the atherosclerotic process, and platelet activation, responsible for acute thrombotic events. In this study, we characterized the antiplatelet effects of the new 5-lipoxygenase/cyclooxygenase inhibitor licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3,dihydro-1H- pyrrolizine-5-yl]-acetic acid. Licofelone completely prevented platelet aggregation induced in platelet-rich plasma by threshold aggregating concentrations of arachidonic acid (0.87±0.14 mM) at threshold inhibitory concentrations of 0.75±0.35 μM (n=5). Platelet-rich plasma aggregation induced by threshold aggregating concentrations of collagen/adrenalin (0.3±0.05 μg/ml and 0.4±0.1 μM, respectively) was reduced to 3.2±2{\%} of control at licofelone 100 μM, (P2 (TxB2) production by all the agonists tested at concentrations between 0.5 and 50 μM. At this concentration, TxB2 production was reduced at values similar to those of unstimulated platelets. These results indicate that, at clinically relevant concentrations, licofelone exerts a potent antiplatelet effect mediated by the inhibition of cyclooxygenase-1 activity.",
keywords = "Cyclooxygenase-lipoxygenase inhibitor, Licofelone, Platelet aggregation, human, Thromboxane A2",
author = "Serenella Rotondo and Katarzyna Krauze-Brz{\'o}sko and Stefano Manarini and Virgilio Evangelista and Chiara Cerletti",
year = "2004",
month = "3",
day = "19",
doi = "10.1016/j.ejphar.2004.02.006",
language = "English",
volume = "488",
pages = "79--83",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation

AU - Rotondo, Serenella

AU - Krauze-Brzósko, Katarzyna

AU - Manarini, Stefano

AU - Evangelista, Virgilio

AU - Cerletti, Chiara

PY - 2004/3/19

Y1 - 2004/3/19

N2 - 5-Lipoxygenase/cyclooxygenase inhibitors, possessing anti-inflammatory action and gastric safety due to cyclooxygenase-2 and 5-lipoxygenase inhibition and antiplatelet activity due to cyclooxygenase-1 blockade, would be beneficial in the treatment of ischemic disease because they may reduce, at the same time, inflammation, underlying the atherosclerotic process, and platelet activation, responsible for acute thrombotic events. In this study, we characterized the antiplatelet effects of the new 5-lipoxygenase/cyclooxygenase inhibitor licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3,dihydro-1H- pyrrolizine-5-yl]-acetic acid. Licofelone completely prevented platelet aggregation induced in platelet-rich plasma by threshold aggregating concentrations of arachidonic acid (0.87±0.14 mM) at threshold inhibitory concentrations of 0.75±0.35 μM (n=5). Platelet-rich plasma aggregation induced by threshold aggregating concentrations of collagen/adrenalin (0.3±0.05 μg/ml and 0.4±0.1 μM, respectively) was reduced to 3.2±2% of control at licofelone 100 μM, (P2 (TxB2) production by all the agonists tested at concentrations between 0.5 and 50 μM. At this concentration, TxB2 production was reduced at values similar to those of unstimulated platelets. These results indicate that, at clinically relevant concentrations, licofelone exerts a potent antiplatelet effect mediated by the inhibition of cyclooxygenase-1 activity.

AB - 5-Lipoxygenase/cyclooxygenase inhibitors, possessing anti-inflammatory action and gastric safety due to cyclooxygenase-2 and 5-lipoxygenase inhibition and antiplatelet activity due to cyclooxygenase-1 blockade, would be beneficial in the treatment of ischemic disease because they may reduce, at the same time, inflammation, underlying the atherosclerotic process, and platelet activation, responsible for acute thrombotic events. In this study, we characterized the antiplatelet effects of the new 5-lipoxygenase/cyclooxygenase inhibitor licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3,dihydro-1H- pyrrolizine-5-yl]-acetic acid. Licofelone completely prevented platelet aggregation induced in platelet-rich plasma by threshold aggregating concentrations of arachidonic acid (0.87±0.14 mM) at threshold inhibitory concentrations of 0.75±0.35 μM (n=5). Platelet-rich plasma aggregation induced by threshold aggregating concentrations of collagen/adrenalin (0.3±0.05 μg/ml and 0.4±0.1 μM, respectively) was reduced to 3.2±2% of control at licofelone 100 μM, (P2 (TxB2) production by all the agonists tested at concentrations between 0.5 and 50 μM. At this concentration, TxB2 production was reduced at values similar to those of unstimulated platelets. These results indicate that, at clinically relevant concentrations, licofelone exerts a potent antiplatelet effect mediated by the inhibition of cyclooxygenase-1 activity.

KW - Cyclooxygenase-lipoxygenase inhibitor

KW - Licofelone

KW - Platelet aggregation, human

KW - Thromboxane A2

UR - http://www.scopus.com/inward/record.url?scp=1642397257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642397257&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2004.02.006

DO - 10.1016/j.ejphar.2004.02.006

M3 - Article

C2 - 15044038

AN - SCOPUS:1642397257

VL - 488

SP - 79

EP - 83

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -